-
Ivermectin Assay Design: From Dose to Readout
2026-09-11
Ivermectin assay design requires more than selecting a concentration: solvent control, parasite stage, exposure duration, and orthogonal endpoints all shape interpretation. This guide combines rigorous anti-parasitic research practice with assay lessons from a pivotal GSDMC pancreatic cancer study, without overstating cross-domain evidence.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-10
This FASEB Journal study presents chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The work connects bladder-restricted delivery with tumor-suppressor restoration, cell-cycle inhibition, DNA-damage signaling, and reduced systemic exposure, while also defining important preclinical limitations.
-
Firefly Luciferase mRNA: Reliable Cell Assays
2026-09-10
Learn how EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, can improve reporter-based cell viability, proliferation, and cytotoxicity workflows through defined capping, nucleotide modification, and handling practices. This scenario-driven guide connects transcript design, delivery controls, signal interpretation, and practical product selection.
-
Amplex Red Workflows for H2O2 Assays
2026-09-09
Amplex Red converts hydrogen peroxide into a fluorescent resorufin signal, supporting sensitive enzyme, cell, mitochondrial, and protein-engineering workflows. The reference study shows how an improved peroxidation format can move beyond routine ROS measurement into rapid screening of peroxide-dependent cytochrome P450 variants.
-
Thrombin B Chain Fragment Assay Workflows
2026-09-09
Build more reliable thrombin research workflows with a defined 17-residue B-chain fragment for peptide standards, binding studies, immunoassay controls, and LC-MS method development. Because this reagent is not intact active thrombin, it is especially valuable as a specificity control alongside functional coagulation assays.
-
Septin4, VHL, and HIF-1α in Cardiomyocyte Apoptosis
2026-09-08
The reference study identifies Septin4 as a previously unrecognized regulator of HIF-1α stability in hypoxia-exposed cardiomyocytes. Rather than acting only through its established proapoptotic partners, Septin4 enhances VHL-dependent ubiquitination and degradation of HIF-1α, thereby weakening a cardioprotective hypoxia response and increasing apoptosis.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Assay Reliability
2026-09-08
Learn how EZ Cap™ Cy5 EGFP mRNA (5-moUTP), SKU R1011, separates mRNA uptake from functional translation in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide combines product specifications with published electroporation evidence to improve controls, interpretation, and day-to-day reproducibility.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus
2026-09-07
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides an in vitro transcription workflow for producing randomly Cy3-modified RNA probes for fluorescence-based detection. It is intended for research applications such as in situ hybridization and Northern blot hybridization, not for diagnostic, clinical, therapeutic, or medical use.
-
Degarelix acetate: Assay Workflows and Insights
2026-09-05
Build reproducible GnRH receptor blockade assays that connect receptor binding, pituitary hormone regulation, and prostate cancer research. This guide translates a clinically relevant testosterone-bounce finding into practical sampling, controls, troubleshooting, and translational study design.
-
Palomid 529 (P529) for PI3K/Akt/mTOR Studies
2026-09-05
Palomid 529 (P529) is a practical dual mTORC1/mTORC2 probe for connecting pathway signaling with ESCC metastasis, cisplatin resistance, endothelial responses, and radiotherapy enhancement. This workflow-focused guide covers dosing, controls, combination designs, and troubleshooting while separating established product data from hypothesis-generating applications.
-
Cimetidine Beyond Acid: A BBB Assay Strategy
2026-09-04
Cimetidine is more than a histamine-2 receptor antagonist: its context-dependent pharmacology makes it a useful probe for H2 receptor signaling and cancer research. This article translates a 2025 surrogate blood-brain barrier study into practical assay decisions without assuming that in vitro permeability equals clinical brain exposure.
-
Wnt agonist 1: Experimental Workflow Guide
2026-09-04
Wnt agonist 1, also called BML-284, provides a practical gain-of-function tool for testing β-catenin-dependent transcription, differentiation, and developmental phenotypes. This guide connects controlled Wnt signaling pathway activation with mechanistic assays inspired by a lung cancer brain-metastasis study linking Wnt/NR2F2 signaling to GPX4 regulation and platinum resistance.
-
Cyanine 5-dCTP: From Labeling to Assay Design
2026-09-03
Cyanine 5-dCTP enables red-fluorescent DNA labeling, but its greatest value emerges when nucleotide chemistry, enzyme accessibility, and optical readout are designed together. This article translates DNA-framework research into practical decisions for PCR, sequencing, imaging, and nucleic acid detection.
-
Multiomics Dissection of Acute Liver Injury Therapies
2026-09-03
The reference study integrates co-expression modules, transcriptomics, and proteomics to compare how bifendate and muaddil sapra respond to CCl4-induced acute liver injury. Its main contribution is a systems-level view that separates shared disease modules from drug-associated regulatory and protein changes, offering a framework for mechanism-focused liver injury research.
-
Grazoprevir hydrate: From Protease Signal to Study Design
2026-09-02
Grazoprevir hydrate, also known as MK-5172 hydrate, is examined here through a translational lens: how NS3/4A inhibition, genotype-dependent potency, pharmacokinetics, and resistance biology should shape HCV research decisions. The article connects molecular activity with clinically relevant assay design without reducing the compound to a single EC₅₀ value.